Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to exposures observed in Phase 1 healthy volunteer study GT-02287 was generally well-tolerated with no treatment emergent serious adverse events (TESAEs); no changes recommended from two independent DMC reviews Gain to host GT-02287 KOL event on October 14th at 4 p.m. EST BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today presented a poster at the International Congress of Parkinson’s Disease and Movement Disorders® summarizing early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase 1b clinical study
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025GlobeNewswire
- Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]Seeking Alpha
- Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate UpdateGlobeNewswire
GANX
Sec Filings
- 12/3/25 - Form S-8
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- GANX's page on the SEC website